Survival of patients.

A comparison of the survival of patients with del/t13q14 as the sole abnormality detected by karyotype or Southern blotting; +12 or del11q23 detected by karyotype analysis or interphase FISH; loss or mutation of p53 detected by interphase FISH or mutation analysis; and patients with no abnormality using any of the above techniques. The median survival of patients with no abnormality, del/t13q14 as the sole abnormality, +12, del11q23, or p53 loss/mutation was 292, 209, 122, 117, and 47 months, respectively.